FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. The invention discloses a fusion polypeptide comprising a cereblon binding (CRBN) fragment and a tumor antigen-specific chimeric antigen receptor (CAR) fragment. The invention can be used in medicine in the treatment of malignant tumors as an agent that modulates the expression of therapeutic proteins. The invention makes it possible to regulate the expression of proteins by stimulating their proteasomal and/or ubiquitin-dependent degradation.
EFFECT: invention discloses a method of eliminating side effects encountered in cancer therapy using CARs.
44 cl, 18 ex, 34 tbl, 40 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN, AND METHODS OF USE THEREOF | 2019 |
|
RU2829097C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
